In this study, we show that standard combined CDK4/6i and endocrine therapy does not efficiently suppress the growth of ER+ breast cancer cell lines and tumor xenografts resistant to fulvestrant, while the addition of AKTi results in profound growth inhibition. This evidence concerns the gene ESR1 and breast cancer.